Replacement of the hydrophobic part of 9-cis-retinoic acid with cyclic terpenoid moiety results in RXR-selective agonistic activity

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 9, 2011, Pages 2939-2949

  Okitsu, Takashi ^a   Sato, Kana ^a   Iwatsuka, Kinya ^a   Sawada, Natsumi ^a   Nakagawa, Kimie ^a   Okano, Toshio ^a   Yamada, Shoya ^b   Kakuta, Hiroki ^b   Wada, Akimori ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

9 cis Retinoic acid; Agonist; RAR; Rexinoids; RXR

Indexed keywords

1 ISOPROPYL 4 METHYLBICYCLO [3.1.0] HEX 2 EN 3 YL TRIFLUOROMETHANESULFONIC ACID; 1,2,3,4,4A,5 HEXAHYDRO 1,1,5,5 TETRAMETHYL 2,4A METHANONAPHTHALEN 7 YL TRIFLUOROMETHANESULFONIC ACID; 1,7,7 TRIMETHYLBICYCLO [2.2.1] HEPT 2 EN 2 YL TRIFLUOROMETHANESULFONIC ACID; 3 METHYL 6 (1 PROPEN 2 YL) 1 CYCLOHEXEN 1 YL TRIFLUOROMETHANESULFONIC ACID; 3 METHYL 6 (PROPAN 2 YLIDENE) 1 CYCLOHEXEN 1 YL TRIFLUOROMETHANESULFONIC ACID; 3,7 DIMETHYL 9 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPT 2 EN 2 YL) 2,4,6,8 NONATETRAENOIC ACID; 3,7 DIMETHYL 9 (3 METHYL 6 (1 PROPEN 2 YL) 1 CYCLOHEXEN 1 YL) 2,4,6,8 NONATETRAENOIC ACID; 3,7 DIMETHYL 9 (3 METHYL 6 (PROPAN 2 YLIDENE) 1 CYCLOHEXEN 1 YL) 2,4,6,8 NONATETRAENOIC ACID; 3,7 DIMETHYL 9 (4,6,6 TRIMETHYLBICYCLO[3.1.1]HEPT 2 EN 3 YL) 2,4,6,8 NONATETRAENOIC ACID; 3,7 DIMETHYL 9 (6 ISOPROPYL 3 METHYL 1 CYCLOHEXEN 1 YL) 2,4,6,8 NONATETRAENOIC ACID; 4,4A,5,6,7,8 HEXAHYDRO 4,4A DIMETHYL 6 (1 METHYL)ETHENYLNAPHTHALEN 2 YL TRIFLUOROMETHANESULFONIC ACID; 4,6,6 TRIMETHYLBICYCLO [3.1.1] HEPT 2 EN 3 YL TRIFLUOROMETHANESULFONIC ACID; 6 ISOPROPYL 3 METHYL 1 CYCLOHEXEN 1 YL TRIFLUOROMETHANESULFONIC ACID; 6,6 DIMETHYLBICYLO [3.3.1] HEPT 2 EN 2 YL TRIFLUOROMETHANESULFONIC ACID; ALITRETINOIN; ETHYL 3 METHYL 7 (1,2,3,4,4A,5 HEXAHYDRO 1,1,5,5 TETRAMETHYL 2,4A METHANONAPHTHALEN 7 YL) 2,4,6 OCTATRIENOIC ACID; ETHYL 3 METHYL 7 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPT 2 EN 2 YL) 2,4,6 OCTATRIENOIC ACID; ETHYL 3,7 DIMETHYL 9 (1 ISOPROPYL 4 METHYLBICYCLO[3.1.0]HEX 2 EN 3 LY) 2,4,6,8 NONATETRAENOIC ACID; ETHYL 3,7 DIMETHYL 9 (1,7,7 TRIMETHYLBICYCLO [2.2.1] HEPT 2 EN 2 YL) 2,4,6,8 NONATETRAENOIC ACID; ETHYL 3,7 DIMETHYL 9 (3 METHYL 6 (1 PROPEN 2 YL) 1 CYCLOHEXEN 1 YL) 2,4,6,8 NONATETRAENOIC ACID; ETHYL 3,7 DIMETHYL 9 (3 METHYL 6 (PROPAN 2 YLIDENE) 1 CYCLOHEXEN 1 YL) 2,4,6,8 NONATETRAENOIC ACID; ETHYL 3,7 DIMETHYL 9 (4,6,6 TRIMETHYLBICYCLO[3.1.1.1] HEPT 2 EN 3 YL) 2,4,6,8 NONATETRAENOIC ACID; ETHYL 3,7 DIMETHYL 9 (6 ISOPROPYL 3 METHYL 1 CYCLOHEXEN 1 YL) 2,4,6,8 NONATETRAENOIC ACID; ETHYL 3,7 DIMETHYL 9 (6,6 DIMETHYLBICYCLO[3.1.1] HEPT 2 EN 2 YL) 2,4,6,8 NONATETRAENOIC ACID; ETHYL 7 (4,4A,5,6,7,8 HEXAHYDRO 4,4A DIMETHYL 6 (1 METHYL)ETHENYLNAPHTHALEN 2 YL) 3 METHYL 2,4,6 OCTATRIENOIC ACID; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TERPENOID; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENANTIOMER; HYDROPHOBICITY; ISOMERIZATION; MELTING POINT; METABOLIC SYNDROME X; STRUCTURE ACTIVITY RELATION;

BINDING SITES; COMPUTER SIMULATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; RETINOID X RECEPTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TERPENES; TRETINOIN;

EID: 79955478892     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2011.03.033     Document Type: Article

References (24)

1. V. Gigure Endocrinol. Rev. 20 1999 689
2. A.R. de Lera, W. Bourguet, L. Altucci, and H. Gronemeyer Nat. Rev. Drug Disc. 6 2007 811
3. P. Germain, J. Iyer, C. Zechel, and H. Gronemeyer Nature 415 2002 187
4. A.I. Shulman, C. Larson, D.J. Mangelsdolf, and R. Ranganathan Cell 116 2004 417
5. A.I. Shulman, and D.J. Mangelsdolf N. Eng. J. Med. 353 2005 604
6. L. Altucci, M.D. Leibowitz, K.M. Ogilvie, A.R. de Lera, and H. Gronemeyer Nat. Rev. Drug Disc. 6 2007 793
7. R. Alvarez, M.J. Vega, S. Kammerer, A. Rossin, P. Germain, H. Gronemeyer, and A.R. de Lera Bioorg. Med. Chem. Lett. 14 2004 6117
8. S. Álvarez, Y. Pazos-Randulfe, H. Khanwalkar, P. Germain, R. Álvarez, H. Gronemeyer, and A.R. de Lera Bioorg. Med. Chem. 16 2008 9719
9. T. Okitsu, K. Iwatsuka, and A. Wada Chem. Commun. 2008 6330
10. T. Okitsu, D. Nakazawa, K. Nakagawa, T. Okano, and A. Wada Chem. Pharm. Bull. 58 2010 418
11. A. Wada, N. Matsuura, Y. Mizuguchi, K. Nakagawa, M. Ito, and T. Okano Bioorg. Med. Chem. 16 2008 8471
12. A. Wada, Y. Mizuguchi, H. Miyake, M. Niihara, M. Ito, K. Nakagawa, and T. Okano Lett. Drug Des. Discov. 4 2007 442
13. A. Wada, Y. Mizuguchi, M. Shinmen, M. Ito, K. Nakagawa, and T. Okano Lett. Drug Des. Discov. 3 2006 118
14. A. Wada, K. Fukunaga, M. Ito, Y. Mizuguchi, K. Nakagawa, and T. Okano Bioorg. Med. Chem. 12 2004 3931
15. Y. Pazos, B. Iglesias, and A.R. de Lera J. Org. Chem. 66 2001 8483
16. S.P.H. Mee, V. Lee, and J.K. Baldwin Chem. Eur. J. 11 2005 3294
17. S.P.H. Mee, V. Lee, and J.K. Baldwin Angew. Chem., Int. Ed. 43 2004 1132
18. P. Germain, P. Chambon, G. Eichele, R.M. Evans, M.A. Lazar, M. Leid, A.R. de Lera, R. Lotan, D.J. Mangelsdolf, and H. Gronemeyer Pharmacol. Rev. 58 2006 760
19. R. Kurokawa, M. Söderström, A. Hörlein, S. Halachimi, M. Brown, M.G. Rosenfeld, and C.K. Glass Nature 377 1995 451
20. S. Westin, R. Kurokawa, R.T. Nolte, G.B. Wisely, Mclnerney, D.W. Mclnerney, M.V. Milburn, M.G. Rosenfeld, and C.K. Glass Nature 395 1998 199
21. N.J. Mckenna, and B.W. O'Malley Cell 108 2002 465
22. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson J. Comput. Chem. 30 2009 2785
23. L.A. Paquette, C.S. Ra, and S.D. Edomonson J. Org. Chem. 55 1990 2443
24. T. Bunlaksananusorn, and P. Knochel J. Org. Chem. 69 2004 4595